Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025).

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Telix’s Precision Medicine business delivered excellent sequential growth in Q4 2025, driven in part by the successful U.S. launch of Gozellix. This revenue growth outpaced a 3% increase in dose volumes, demonstrating the positive impact of our two-product strategy on market share and pricing. With strong early uptake of Gozellix and a robust pipeline of key accounts integrating Gozellix and ARTMS technology, Telix is well positioned for sustained growth in 2026.”

In line with its stated strategy to invest in supply chain and production capabilities to meet future demand for radiopharmaceuticals, Telix is progressing several key projects:

These investments support vertical integration, supply chain control, and global centers of excellence for advancing Telix’s next-generation therapeutic radiopharmaceutical portfolio.

Telix announced a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology. The collaboration focuses on developing novel clinical applications that combine Telix’s theranostic products with EBRT, starting with PSMA-PET imaging for prostate cancer. This framework supports future co-development opportunities, including with other PET imaging candidates in Telix’s pipeline (TLX250-Px and TLX101-Px) and potential future therapeutic radiopharmaceuticals.

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix has been approved by the FDA30, and in multiple markets globally. Gozellix has been approved by the FDA31. No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction.

Visitwww.telixpharma.comfor further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix onLinkedIn,XandFacebook.

Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail:kyahn.williamson@telixpharma.com

Annie KasparianTelix Pharmaceuticals LimitedDirector Investor Relations and Corporate CommunicationsEmail:annie.kasparian@telixpharma.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

_________________________________1Converted at the full year 2025 average US$:A$ exchange rate of 1.55:12Telix ASX disclosure 14 October 2025.3Telix ASX disclosure 23 September 2025.4Telix media release 8 December 2025. ClinicalTrials.gov ID:NCT06520345.5Telix media release 23 October 2025. ClinicalTrials.gov ID:NCT07197645.6Telix media release 10 December 2025.7Primarily sales of Illuccix and Gozellix in our Precision Medicine business.8RLS Radiopharmacies revenue excludes revenue contribution from Illuccix and Gozellix sales.9Japanese regulator Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval for a Japan-specific Part 1 in nine patients, prior to commencing Part 2.10ClinicalTrials.gov ID:NCT07197580.11ClinicalTrials.gov ID:NCT07100730.12Telix media release 23 October 2025.13Telix media release 29 August 2025.14Imaging of prostate-specific membrane antigen.15Management estimate based on Medicare Benefit Schedule statistics, available at:medicarestatistics.humanservices.gov.au/16Telix ASX disclosure 20 January 2026.17ClinicalTrials.gov ID:NCT05847348.18Telix ASX disclosure 22 December 2025, Telix data on file. Illuccix China Clinical Study Report, December 2025.19Biopsy of the Prostate Avoidance Stratification Study; ClinicalTrials.gov ID:NCT07052214. Telix media release 16 January 2026.20Japan Registry of Clinical Trials identifier: JRCT203125047321Brand name subject to final regulatory approval.22ClinicalTrials.gov ID:NCT06743100.23Telix ASX disclosure 22 December 2025.24ClinicalTrials.gov ID:NCT03849118.25Rowe et al.J Nucl Med.2025. Telix media release 23 October 2025.26Telix ZIRCON-X SUO 2025 abstract, available at: https://suo-abstracts.secure-platform.com/a/gallery/rounds/24/details/486927ClinicalTrials.gov ID:NCT06090331.28Telix media release 21 November 2025.29Single-photon emission computed tomography combined with computed tomography.30Telix ASX disclosure 20 December 2021.31Telix ASX disclosure 21 March 2025.